Your browser doesn't support javascript.
loading
Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer.
Kang, Byeongju; Lee, Jeeyeon; Jung, Jin Hyang; Kim, Wan Wook; Keum, Heejung; Park, Ho Yong.
Afiliación
  • Kang B; Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
Medicine (Baltimore) ; 102(34): e34772, 2023 Aug 25.
Article en En | MEDLINE | ID: mdl-37653831
The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared the clinicopathologic factors and survival rates of different subtypes of luminal B breast cancer according to HER2 status. Between 2009 and 2013, 1131 cases of breast cancer were reviewed and characterized as 1 of 4 different molecular subtypes based on their immunohistochemical results: luminal A, luminal B, HER2+, or triple-negative breast cancer. From these, luminal B breast cancers were extracted and the clinical features and prognosis of the HER2- and the HER2 + subtypes were compared. Survival differed significantly based on the molecular subtype regardless of whether or not the patient received treatment with neoadjuvant chemotherapy. While patients with HER2- luminal B breast cancer who received neoadjuvant chemotherapy had better prognoses, patients with HER2 + luminal B breast cancer who did not receive neoadjuvant chemotherapy had better prognoses. Luminal B breast cancers showed different clinical outcomes and survival rates according to HER2 gene overexpression type. Physicians should consider these results when they establish a treatment strategy.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Médicos / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Idioma: En Revista: Medicine (Baltimore) Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Médicos / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Idioma: En Revista: Medicine (Baltimore) Año: 2023 Tipo del documento: Article